Jawad Haider, MD
Interventional Cardiology · Bloomfield, CTNPI 1194773564
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by AstraZeneca at 42.3% of the total. Reporting peaked in 2020 at $17,115 and has fallen 82.2% since, to $3,048 in 2025. Among interventional cardiology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 678 payments — averaging $64.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$19K
- Abbott$7K
- Boston Scientific$6K
- Edwards Lifesciences$5K
- Medtronic$2K
- Baylis Medical Company Inc$1K
- plus $5K from 34 others
Across 14 payments — averaging $23,505 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$329K
What the payments were for
- Consulting fees$2,4366%
- Speaking & faculty fees$17,40040%
- Travel & lodging$5,98314%
- Food & beverage$18,17841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$17,525
- CardioMEMS HF System$2,436
- MitraClip$1,232
- VersaCross Access Solution$959
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$775
- Carto 3$603
- WATCHMAN Access System$583
- WATCHMAN FLX$519
- CARDIOMEMS$432
- Edwards SAPIEN 3 Transcatheter Heart Valve$423
- APOLLOTM$313
- Confirm Rx$296
- Watchman$283
- AMPLATZER Occluders$174
- Ultreon$173
- AMPLATZER AMULET$163
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$162
- SYMPLICITY G3$159
- FFRct$150
- JOT DX$148
How this compares
$43,997 in reported general payments places this provider in the 95th percentile of 73 interventional cardiology providers in Connecticut.
See all interventional cardiology providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 40 | $60,605 |
| Repatha SureclickEvolocumab | 47 | $55,654 |
| FarxigaDapagliflozin Propanediol | 11 | $17,987 |
| VascepaIcosapent Ethyl | 11 | $6,334 |
| Ezetimibe | 58 | $1,081 |
| Atorvastatin Calcium | 65 | $789 |
| Metoprolol Succinate | 43 | $722 |
| Amlodipine Besylate | 68 | $475 |
| Rosuvastatin Calcium | 40 | $373 |
| Carvedilol | 48 | $340 |
| Losartan Potassium | 42 | $322 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 11 | $311 |
| ClopidogrelClopidogrel Bisulfate | 15 | $145 |
| Lisinopril | 29 | $134 |
| Metoprolol Tartrate | 13 | $121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $347 | $60,60540 claims |
| AstraZenecaFarxiga | $18,617 | $17,98711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 73 interventional cardiology providers in Connecticut.
Other interventional cardiology in Bloomfield
- Patrick CorcoranBloomfield$12K
- Amit VoraNew Haven$409K
- Craig ThompsonHartford$222K
- Michael NannaNew Haven$60K
- Sameer NagpalNew Haven$43K
- Khagendra DahalFarmington$42K
- Abdul QaziHartford$38K
- Sarfaraz MemonHartford$30K
- Edward CarrerasStratford$30K
- Michael ChrissoherisNew Haven$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.